Most Recent
Bayer faces appeals of IP Australia rulings on antiseptic patent
Intellectual Property 2019-06-04 3:24 pm By Miklos Bolza

Veterinary pharmaceutical companies Norbrook Laboratories and Merial have launched twin appeals of two IP Australia decisions allowing Bayer to amend a proposed patent for a treatment for mammary gland infections.

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Contact us to enquire about group subscriptions.

Novartis patent for oral form of top-selling MS drug obvious, IP Australia says
Intellectual Property 2019-05-13 12:31 pm By Miklos Bolza

A proposed Novartis patent for an oral form of its top-selling multiple sclerosis drug Gilenya is invalid for lack of inventive step, IP Australia has found, but gave the pharmaceutical giant a chance to amend.

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Contact us to enquire about group subscriptions.